Oncolytics Historical Balance Sheet

ONCY Stock

USD 0.95 0.03 3.06%

Trend analysis of Oncolytics Biotech balance sheet accounts such as Total Stockholder Equity of 17.8 M provides information on Oncolytics Biotech's total assets, liabilities, and equity, which is the actual value of Oncolytics Biotech to its prevalent stockholders. By breaking down trends over time using Oncolytics Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oncolytics Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oncolytics Biotech is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

About Oncolytics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Oncolytics Biotech at a specified time, usually calculated after every quarter, six months, or one year. Oncolytics Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Oncolytics Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Oncolytics currently owns. An asset can also be divided into two categories, current and non-current.

Oncolytics Biotech Balance Sheet Chart

At this time, Oncolytics Biotech's Common Stock Shares Outstanding is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 7.4 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.

Total Assets Total Current Liabilities Property Plant And Equipment Net Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Oncolytics Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Oncolytics Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Oncolytics Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oncolytics Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Oncolytics Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Oncolytics Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Oncolytics Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Common Stock Shares Outstanding is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 7.4 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024.

	2021	2022	2023	2024 (projected)
Cash	41.3M	11.7M	34.9M	19.4M
Accounts Payable	594K	2.3M	1.1M	1.0M

Cash Accounts Payable

Oncolytics Biotech balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Current Liab	Net Tangible Assets	Common Stock Total Equity	Short Term Investments	Common Stock	Property Plant Equipment	Non Currrent Assets Other
Total Assets		0.14	0.01	0.9	0.74	-0.84	-0.62	-0.07	0.84	-0.13	0.98	-0.15	0.7	0.46	0.62	0.66	0.32	0.45	1.0	0.17	0.68	0.44	0.33	0.66	0.7	0.6
Short Long Term Debt Total	0.14		0.02	-0.1	0.41	-0.04	-0.58	-0.59	0.05	0.01	0.03	0.4	0.48	0.75	0.56	0.54	0.58	0.49	0.14	0.24	0.49	0.56	0.22	0.54	0.53	0.19
Total Current Liabilities	0.01	0.02		-0.3	0.29	0.02	-0.15	0.26	0.0	-0.39	-0.03	0.34	-0.11	0.09	0.19	0.22	0.71	0.37	0.03	0.77	-0.38	0.05	0.11	0.1	0.32	-0.04
Total Stockholder Equity	0.9	-0.1	-0.3		0.51	-0.78	-0.33	0.09	0.82	-0.04	0.94	-0.33	0.48	0.12	0.29	0.37	-0.1	0.1	0.9	-0.16	0.58	0.18	0.17	0.39	0.44	0.58
Property Plant And Equipment Net	0.74	0.41	0.29	0.51		-0.58	-0.75	-0.26	0.63	-0.23	0.7	0.04	0.59	0.59	0.65	0.76	0.64	0.61	0.76	0.36	0.58	0.65	0.37	0.73	0.94	0.51
Net Debt	-0.84	-0.04	0.02	-0.78	-0.58		0.46	0.03	-0.95	0.35	-0.86	0.26	-0.54	-0.31	-0.58	-0.48	-0.13	-0.4	-0.84	-0.13	-0.56	-0.34	-0.06	-0.53	-0.52	-0.23
Retained Earnings	-0.62	-0.58	-0.15	-0.33	-0.75	0.46		0.36	-0.39	0.35	-0.55	-0.11	-0.84	-0.81	-0.8	-0.98	-0.6	-0.69	-0.62	-0.2	-0.78	-0.94	-0.41	-0.99	-0.72	-0.24
Accounts Payable	-0.07	-0.59	0.26	0.09	-0.26	0.03	0.36		0.02	-0.45	0.03	-0.05	-0.51	-0.68	-0.61	-0.24	-0.29	-0.62	-0.03	-0.24	-0.52	-0.44	-0.38	-0.37	-0.27	0.07
Cash	0.84	0.05	0.0	0.82	0.63	-0.95	-0.39	0.02		-0.34	0.87	-0.22	0.41	0.23	0.47	0.42	0.18	0.29	0.86	0.15	0.46	0.24	0.1	0.42	0.59	0.3
Non Current Assets Total	-0.13	0.01	-0.39	-0.04	-0.23	0.35	0.35	-0.45	-0.34		-0.18	-0.14	0.07	0.05	-0.04	-0.39	-0.19	0.08	-0.18	-0.08	0.06	-0.29	0.13	-0.31	-0.14	0.28
Cash And Short Term Investments	0.98	0.03	-0.03	0.94	0.7	-0.86	-0.55	0.03	0.87	-0.18		-0.29	0.62	0.34	0.52	0.59	0.21	0.35	0.99	0.09	0.62	0.37	0.28	0.59	0.64	0.57
Net Receivables	-0.15	0.4	0.34	-0.33	0.04	0.26	-0.11	-0.05	-0.22	-0.14	-0.29		-0.1	0.24	0.12	0.14	0.43	0.06	-0.14	0.28	-0.11	0.11	-0.05	0.05	0.06	-0.05
Common Stock Shares Outstanding	0.7	0.48	-0.11	0.48	0.59	-0.54	-0.84	-0.51	0.41	0.07	0.62	-0.1		0.81	0.88	0.81	0.39	0.77	0.67	0.11	0.92	0.79	0.37	0.89	0.62	0.35
Non Current Liabilities Total	0.46	0.75	0.09	0.12	0.59	-0.31	-0.81	-0.68	0.23	0.05	0.34	0.24	0.81		0.88	0.77	0.71	0.78	0.44	0.36	0.69	0.76	0.47	0.8	0.66	0.24
Other Current Assets	0.62	0.56	0.19	0.29	0.65	-0.58	-0.8	-0.61	0.47	-0.04	0.52	0.12	0.88	0.88		0.76	0.64	0.93	0.6	0.47	0.75	0.74	0.39	0.83	0.69	0.17
Other Stockholder Equity	0.66	0.54	0.22	0.37	0.76	-0.48	-0.98	-0.24	0.42	-0.39	0.59	0.14	0.81	0.77	0.76		0.63	0.64	0.66	0.23	0.72	0.87	0.31	0.97	0.74	0.32
Total Liab	0.32	0.58	0.71	-0.1	0.64	-0.13	-0.6	-0.29	0.18	-0.19	0.21	0.43	0.39	0.71	0.64	0.63		0.69	0.33	0.76	0.16	0.49	0.44	0.54	0.72	0.19
Property Plant And Equipment Gross	0.45	0.49	0.37	0.1	0.61	-0.4	-0.69	-0.62	0.29	0.08	0.35	0.06	0.77	0.78	0.93	0.64	0.69		0.43	0.62	0.57	0.65	0.35	0.7	0.65	0.12
Total Current Assets	1.0	0.14	0.03	0.9	0.76	-0.84	-0.62	-0.03	0.86	-0.18	0.99	-0.14	0.67	0.44	0.6	0.66	0.33	0.43		0.17	0.66	0.43	0.33	0.66	0.71	0.59
Other Current Liab	0.17	0.24	0.77	-0.16	0.36	-0.13	-0.2	-0.24	0.15	-0.08	0.09	0.28	0.11	0.36	0.47	0.23	0.76	0.62	0.17		-0.13	0.03	0.3	0.17	0.4	0.0
Net Tangible Assets	0.68	0.49	-0.38	0.58	0.58	-0.56	-0.78	-0.52	0.46	0.06	0.62	-0.11	0.92	0.69	0.75	0.72	0.16	0.57	0.66	-0.13		0.75	0.32	0.82	0.57	0.39
Common Stock Total Equity	0.44	0.56	0.05	0.18	0.65	-0.34	-0.94	-0.44	0.24	-0.29	0.37	0.11	0.79	0.76	0.74	0.87	0.49	0.65	0.43	0.03	0.75		0.36	0.93	0.6	0.08
Short Term Investments	0.33	0.22	0.11	0.17	0.37	-0.06	-0.41	-0.38	0.1	0.13	0.28	-0.05	0.37	0.47	0.39	0.31	0.44	0.35	0.33	0.3	0.32	0.36		0.39	0.38	0.17
Common Stock	0.66	0.54	0.1	0.39	0.73	-0.53	-0.99	-0.37	0.42	-0.31	0.59	0.05	0.89	0.8	0.83	0.97	0.54	0.7	0.66	0.17	0.82	0.93	0.39		0.69	0.26
Property Plant Equipment	0.7	0.53	0.32	0.44	0.94	-0.52	-0.72	-0.27	0.59	-0.14	0.64	0.06	0.62	0.66	0.69	0.74	0.72	0.65	0.71	0.4	0.57	0.6	0.38	0.69		0.52
Non Currrent Assets Other	0.6	0.19	-0.04	0.58	0.51	-0.23	-0.24	0.07	0.3	0.28	0.57	-0.05	0.35	0.24	0.17	0.32	0.19	0.12	0.59	0.0	0.39	0.08	0.17	0.26	0.52

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Total Current Liabilities	12.9M	2.7M	2.7M	3.9M	4.2M	3.9M
Total Stockholder Equity	(107.9K)	24.8M	36.1M	26.5M	27.6M	17.8M
Property Plant And Equipment Net	727.5K	609.1K	976.3K	652K	647K	460.6K
Net Debt	(13.6M)	(30.8M)	(40.6M)	(11.3M)	(34.5M)	(32.8M)
Retained Earnings	(344.6M)	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(423.7M)
Accounts Payable	3.2K	1.8K	594K	2.3M	1.1M	1.0M
Cash	14.1M	31.2M	41.3M	11.7M	34.9M	19.4M
Non Current Assets Total	727.5K	609.1K	976.3K	1.7M	647.0K	614.6K
Cash And Short Term Investments	14.1M	31.2M	41.3M	32.1M	34.9M	26.6M
Net Receivables	2.1M	89.7K	866.1K	521K	15K	14.3K
Common Stock Shares Outstanding	22.1M	40.3M	53.5M	58.0M	67.6M	71.0M
Liabilities And Stockholders Equity	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Non Current Liabilities Total	6.9M	6.9M	7.1M	6.9M	7.0M	7.4M
Other Current Assets	2.7M	2.4M	2.8M	1.7M	3.2M	3.4M
Other Stockholder Equity	33.0M	31.0M	37.8M	40.1M	42.1M	38.1M
Total Liab	19.8M	9.6M	9.8M	10.8M	11.3M	6.0M
Property Plant And Equipment Gross	1.7M	609.1K	976.3K	652K	1.3M	1.4M
Total Current Assets	18.9M	33.7M	44.9M	35.7M	38.2M	28.0M
Accumulated Other Comprehensive Income	464.1K	400.2K	387.7K	662K	544K	516.8K
Other Current Liab	12.5M	2.5M	1.8M	1.5M	3.0M	1.9M
Other Liab	4.6M	5.9M	6.7M	6.7M	7.7M	8.1M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	32.0M
Common Stock Total Equity	271.7M	285.2M	311.1M	356.8M	410.3M	430.9M
Short Term Investments	13.1M	30.4M	1.4M	20.5M	3.4M	3.2M
Short Term Debt	339.8K	248.9K	294K	216K	133K	127.3K
Common Stock	311.1M	356.8M	391.3M	404.0M	430.9M	452.5M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	377.8K
Capital Lease Obligations	506.3K	402.1K	654.8K	373K	423K	288.3K
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	(107.9K)	24.8M	36.1M	26.5M	27.6M	20.3M
Net Working Capital	6.1M	31.0M	42.2M	31.7M	33.9M	26.6M
Capital Stock	311.1M	356.8M	391.3M	404.0M	430.9M	399.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Historical Balance Sheet

About Oncolytics Balance Sheet Analysis

Oncolytics Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accounts Payable

Oncolytics Biotech balance sheet Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech balance sheet Accounts

Also Currently Popular

Additional Tools for Oncolytics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock	+ 0.97	Other Stockholder Equity
Cash And Short Term Investments	+ 0.94	Total Stockholder Equity
Property Plant Equipment	+ 0.94	Property Plant And Equipment Net

Common Stock	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.95	Net Debt
Common Stock Total Equity	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.86	Net Debt
Common Stock Shares Outstanding	- 0.84	Retained Earnings